IP Library Granted Patent US 7,618,963
Granted Patent B2
US 7,618,963 · App. 11/788,886 · Granted Nov 17, 2009

Bicyclic heteroaromatic compounds

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,618,963
App. No.
11/788,886
Granted
Nov 17, 2009
Kind
B2
Abstract

A bicyclic heteroaromatic compound according to general formula I, or a pharmaceutically acceptable salt thereof, wherein R1 is (3-8C)cycloalkyl, (2-7C)heterocycloalkyl, (6-14C)aryl or (4-13C)heteroaryl; all optionally substituted with one or more substituents; R2 is (1-4C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl, (6-14C)aryl or (4-13C)heteroaryl; R3 is (1-8C)alkyl, (3-8C)cycloalkyl, (2-7C)heterocycloalkyl, (6-14C)aryl or (4-13C)heteroaryl; Y is CH or N; Z is NH2 or OH; A is S, N(H), N(R), O or a bond and B is N(H), O or a bond; X1-X2 is C═C, C(O)—NH, NH—C(O), C(O)—O, O—C(O), C═N, N═C or S or O. The compounds of the invention can be used in fertility regulation therapies.

Claims (24)

1. A bicyclic heteroaromatic compound according to general formula I, or a pharmaceutically acceptable salt thereof,

wherein

R 1 is (3-8C)cycloalkyl, (2-7C)heterocycloalkyl, (6-14C)aryl or (4-13C)heteroaryl; all optionally substituted with one or more substituents selected from N(R 4 )R 5 , NHR 5 , R 5 , OR 5 and/or SR 5 ;

R 2 is (1-4C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl, (6-14C)aryl or (4-13C)heteroaryl;

R 3 is (1-8C)alkyl, (3-8C)cycloalkyl, (2-7C)heterocycloalkyl, (6-14C)aryl or (4-13C)heteroaryl;

R 4 can be selected from the same groups as described for R 2 ,

R 5 is (2-7C)heterocycloalkylcarbonyl, (2-8C)alkenylsulfonyl, (2-8C)alkenoxycarbonyl, (6-14C)arylsulfonyl, (6-14C)arylaminocarbonyl, (6-14C)aryloxycarbonyl, (6-14C)arylaminosulfonyl, (6-14C)aryloxysulfonyl, or

(1-8C)alkylsulfonyl, (1-8C)(di)alkylaminocarbonyl, (1-8C)alkoxycarbonyl, (1-8C)(di)alkylaminosulfonyl, or (1-8C)alkoxysulfonyl,

the alkyl group of which may be optionally substituted with one or more substituents selected from hydroxyl, (1-8C)alkoxy, (2-7C)heterocycloalkyl(1-8C)alkoxy, (3-8C)cycloalkyl(1-8C)alkoxy, (6-14C)aryl(1-8C)alkoxy, (4-13C)heteroaryl(1-8C)alkoxy, (2-7C)heterocycloalkyl, (3-8C)cycloalkyl, (6-14C)aryl, (4-13C)heteroaryl, (1-8C)alkoxycarbonyl, (6-14C)aryloxycarbonyl, (1-8C)alkylcarbonyloxy, (6-14C)arylcarbonyloxy, (1-8C)alkylcarbonyl, (6-14C)arylcarbonyl, amine, (1-8C)alkylaminocarbonyl, (6-14C)arylaminocarbonyl, (1-8C)alkylcarbonylamino, (6-14C)arylcarbonylamino, (6-14C)(di)arylamino, (di)[(1-3C)alkoxy(1-3C)alkyl]amino and/or (1-8C)(di)alkylamino;

Y is N;

Z is NH 2 or OH;

A is S, N(H), N(R 4 ), O or a bond;

B is N(H) or a bond; and

X1-X2 is S or O.

2. The compound according to claim 1 , wherein Z is NH 2 .

3. The compound according to claim 1 , wherein R 1 is (6-14C)aryl or (4-13C)heteroaryl, optionally substituted with one or more substituents selected from N(R 4 )R 5 , NHR 5 , R 5 , OR 5 or SR 5 .

4. The compound according to claim 3 , wherein R 5 is (2-7C)heterocycloalkylcarbonyl, or (1-8C)(di)alkylaminocarbonyl, the alkyl group of which may be optionally substituted with (2-7C)heterocycloalkyl, (4-13C)heteroaryl, (1-8C)alkoxycarbonyl, (1-8C)alkylaminocarbonyl, (1-8C)alkylcarbonylamino, (6-14C)arylcarbonylamino, amine and/or (1-8C)(di)alkylamino.

5. The compound according to claim 3 , wherein R 1 is phenyl, optionally substituted with one or more substituents.

6. The compound according to claim 5 , wherein R 1 is substituted at the meta position.

7. The compound according to claim 1 , wherein B is N(H), or B is a bond and R 3 is (2-7C)heterocycloalkyl.

8. The compound according to claim 1 , wherein X1-X2 is S.

9. A pharmaceutical composition comprising a bicyclic heteroaromatic compound according to claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable auxiliary.

10. A method of treating infertility in a patient in need thereof comprising:

administering to the patient an effective amount of the compound according to claim 1 or a pharmaceutically acceptable salt thereof.

Assignments (6)
MERGER Recorded Mar 8, 2013
From: ORGANON BIOSCIENCES NEDERLAND B.V.
To: MERCK SHARP & DOHME B.V.
Reel/Frame 029940/0296 →
MERGER Recorded Mar 7, 2013
From: MSD OSS B.V.
To: ORGANON BIOSCIENCES NEDERLAND B.V.
Reel/Frame 029939/0001 →
MERGER Recorded Dec 1, 2011
From: N.V. ORGANON
To: MSD OSS B.V.
Reel/Frame 027307/0482 →
CORRECTIVE ASSIGNMENT TO CORRECT THE SERIAL NUMBER FROM 6086053 TO 11788886 PREVIOUSLY RECORDED ON REEL 019321 FRAME 0565. ASSIGNOR(S) HEREBY CONFIRMS THE SERIAL NUMBER. Recorded May 22, 2007
From: AKZO NOBEL N.V.
To: N.V. ORGANON
Reel/Frame 019327/0384 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 18, 2007
From: AKZO NOBEL INC.
To: N.V. ORGANON
Reel/Frame 019315/0048 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 14, 2007
From: TIMMERS, CORNELIS MARIUS; KARSTENS, WILLEM FREDERIK JOHAN
To: AKZO NOBEL N.V.
Reel/Frame 019289/0222 →